Recorded Chinese product: 羟喜树碱注射液羟喜树碱注射液
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 贵州汉方制药有限公司Chinese legal name: 贵州汉方制药有限公司
主要成分Active Ingredients
- 亚钠Ya Na
- 丙二醇Binger Chun
- 氢氧化钠Qingyang Huana
- 辅料为乙二胺四乙酸二钠Recorded Chinese composition: 辅料为乙二胺四乙酸二钠
药物知识说明
亚钠是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括:丙二醇Binger Chun、亚钠Ya Na、氢氧化钠Qingyang Huana。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品:丙二醇-40961f6d成分药品。
本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 羟喜树碱注射液) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Active ingredients associated with this product: 丙二醇Binger Chun, 亚钠Ya Na, 氢氧化钠Qingyang Huana.
Explore other medicines containing the same ingredient: 丙二醇 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 羟喜树碱注射液Recorded Chinese product: 羟喜树碱注射液
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 5m1:5mg5m1:5 mg
本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 贵州汉方制药有限公司Chinese legal name: 贵州汉方制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20033959
关联实体Relationships
信息来源Source and scope
国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20033959
Manufacturer
Chinese legal name: 贵州汉方制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20033959
生产企业
贵州汉方制药有限公司(国产)
适应症
用于原发性肝癌、胃癌、头颈部癌、膀胱癌及直肠癌。
用法用量
1.静脉注射每次10~30mg,以氯化钠注射液稀释后静脉注射,每日1次,每周3次,6~8周为一个疗程,联合用药本品剂量可适当减少。2.膀胱灌注每次10mg以氯化钠注射液10ml溶解,排尽尿液后灌注,保持2~4小时左右,每周1次,10次为一个疗程。3.胸腹腔注射恶性胸腹水放净后,10~20mg以氯化钠注射液20ml溶解胸腹腔内注入,每周1~2次。
不良反应
1.骨髓抑制:表现为白细胞下降,对红细胞及血小板无明显影响。
禁忌
对本品过敏者禁用。
注意事项
1.不宜用葡萄糖液稀释。 2.为避免膀胱刺激及血尿发生,用药期间应鼓励患者多饮水。
贮藏
遮光、密闭保存。
规格
5m1:5mg
信息来源Source and scope
国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.